Journal article
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study
Abstract
RATIONALE & OBJECTIVE: Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based therapies that slow the progression of chronic kidney disease (CKD) but can cause hyperkalemia. We aimed to evaluate the association of discontinuing RAAS inhibitors after an episode of hyperkalemia and clinical outcomes in patients with CKD.
STUDY DESIGN: Retrospective cohort study.
Authors
Leon SJ; Whitlock R; Rigatto C; Komenda P; Bohm C; Sucha E; Bota SE; Tuna M; Collister D; Sood M
Journal
American Journal of Kidney Diseases, Vol. 80, No. 2, pp. 164–173.e1
Publisher
Elsevier
Publication Date
August 2022
DOI
10.1053/j.ajkd.2022.01.002
ISSN
0272-6386